Skip to main content
. 2022 Mar 3;10(3):391. doi: 10.3390/vaccines10030391

Figure 2.

Figure 2

Neutralizing activities against (a) wild-type, (b) B.1.1.7-alpha, (c) B.1.351-beta, and (d) B.1.617.2-delta using surrogate virus neutralization test (sVNT). The fully vaccinated individuals with two doses of CoronaVac (CV+CV), the fully vaccinated individuals with two doses of CoronaVac then administered a third vaccination with AZD1222 (CV+CV+AZ), and the fully vaccinated individuals with two doses of CoronaVac followed by SARS-CoV-2 breakthrough infection (CV+CV+infection) were compared. Median values with IQRs are shown as horizontal bars. Dotted lines indicate cut-off values, and grey shaded areas depict values under the cut-off. Statistics were calculated using Kruskal–Wallis tests with Dunn’s post hoc correction. * p < 0.05, ** p < 0.01, *** p < 0.001. ns indicates no statistical significance.